Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Alnylam Delivers a Big Q4 Earnings Beat

TheMotleyFool 
0 0 13.02.25
Alnylam Delivers a Big Q4 Earnings Beat
 

Alnylam Pharmaceuticals (NASDAQ:ALNY), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share. Revenue of $593.2 million also outpaced the expected $584 million. This quarter's strong performance was generally fueled by effective product commercialization and strategic execution, despite the complexities Alnylam faced in some market segments.

Source: Analysts' estimates for the quarter provided by FactSet.

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), a cutting-edge technology that targets RNA to silence genes involved in diseases. It has a strong catalog of approved products and a robust pipeline. It focuses on treatments for rare diseases. Collaborations with industry giants such as Regeneron and Novartis support its commercialization and R efforts.

Continue reading


Source Fool.com

Electro Power Systems S.A. Stock

Show more
Like: 0
ALNY
Share

Comments

Not a member yet? Sign up for free!